Actively Recruiting
Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion
Led by Rigshospitalet, Denmark · Updated on 2026-02-09
36
Participants Needed
1
Research Sites
59 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study investigates how the naturally occurring gut hormones GIP and GLP-1 influence whole-body glucose uptake and organ perfusion in humans. Using a state-of-the-art total-body PET-CT scanner, the study measures dynamic uptake of the glucose analogue 18F-FDG and blood flow using H₂¹⁵O across multiple organs during controlled elevations of plasma glucose and endogenous insulin secretion. The project consists of two sub-studies. Sub-study 1 includes healthy individuals who undergo three experimental visits with infusions of GIP, GLP-1, or saline (placebo) during a hyperglycemic clamp followed by FDG PET-CT scanning. Sub-study 2 includes healthy individuals and participants with type 2 diabetes who undergo two experimental visits with saline followed by either GIP or GLP-1 during a hyperglycemic clamp, combined with repeated H₂¹⁵O PET-CT measurements of perfusion. The primary aims are to quantify insulin-mediated skeletal muscle glucose uptake (sub-study 1) and skeletal muscle perfusion (sub-study 2). Secondary aims include assessment of glucose uptake and perfusion across adipose tissue, liver, and additional organs. The results will provide novel physiological insight into postprandial glucose metabolism and serve as reference data for future whole-body PET research.
CONDITIONS
Official Title
Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Sub-study 1: Age 23-50 years
- Sub-study 1: BMI between 20.0 and 26.9 kg/m²
- Sub-study 1: HbA1c less than 42 mmol/mol
- Sub-study 1: Able to provide informed consent
- Sub-study 2 (Type 2 Diabetes): Age 23-60 years
- Sub-study 2 (Type 2 Diabetes): Diagnosed with type 2 diabetes for at least 3 months
- Sub-study 2 (Type 2 Diabetes): HbA1c greater than 53 mmol/mol
- Sub-study 2 (Type 2 Diabetes): Treated with metformin only
- Sub-study 2 (Healthy controls): Age 23-64 years
- Sub-study 2 (Healthy controls): HbA1c less than 42 mmol/mol
- Sub-study 2 (Healthy controls): Able to provide informed consent
You will not qualify if you...
- Anaemia (low haemoglobin)
- ALT liver enzyme more than twice the normal upper limit or known liver or gastrointestinal disorders
- Kidney disease with creatinine above normal range
- Previous major stomach or intestinal surgery (except appendectomy or gallbladder removal) or bariatric surgery
- For Sub-study 1: diagnosis of type 1 or type 2 diabetes or HbA1c 42 mmol/mol or higher
- Use of glucose-lowering drugs other than metformin (Sub-study 2 only)
- Chronic obstructive pulmonary disease (Sub-study 2 only)
- Regular smoking or use of nicotine products
- Claustrophobia
- Pregnancy, breastfeeding, or planning pregnancy during the study
- Starting special diets, major lifestyle changes, or losing more than 5% body weight within 3 months before or during the study
- Any medication or physical/mental condition that may affect participation
- Unable to speak or read Danish
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Copenhagen University Hospital - Rigshospitalet
Copenhagen, Denmark, 2100
Actively Recruiting
Research Team
M
Mathilde Borring Brogaard, Doctor
CONTACT
P
Per Cramon, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here